CD82 and breast cancer: Our finding of low expression of KAI-1 in T3/T4 category is in line with previous studies on breast cancer where they observed lower expression of KAI-1 in advanced T category in comparison of early T category (Singh et al., 2016) and significantly higher transcription levels of KAI-1 in early stage tumours (TNM1) compared with late stage tumours (TNM2, 3 and 4 (Malik et al., 2000).